Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Anthracycline-Associated Cardiotoxicity
NCT06684509Phase 2Not yet recruiting
- Sponsor
- Assiut University
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in Cardiotoxicity (2 arms), sponsored by Assiut University. Primary endpoint: Cardiotoxicity (LVEF) at 12 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT06684509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684509.